Overview Markets Watchlist

© 2026 IR SuperintelMethodology Contact

Entrada Therapeutics Inc

CUSIP: 29384C908 | 3 institutional holders

Quarters

Q3 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025

Compare Detailed Historical Funds Options 13D/13G Peers Targeting Trading Summary Profile